SCHEMBL25811358

SCHEMBL25811358

Cc1[nH]c2ccc(NC(=O)CCN(C)C)cc2c1C

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 8/20 0.73
HTR1F P30939 1/20 0.51
MAPT P10636 3/20 0.49
TNKS O95271 1/20 0.49
PARP1 P09874 1/20 0.49
PARP15 Q460N3 1/20 0.49
PARP14 Q460N5 1/20 0.49
PARP10 Q53GL7 1/20 0.49
PARP12 Q9H0J9 1/20 0.49
TNKS2 Q9H2K2 1/20 0.49
PARP2 Q9UGN5 1/20 0.49
PARP4 Q9UKK3 1/20 0.49
PARP3 Q9Y6F1 1/20 0.49
KMT2A Q03164 1/20 0.49
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
HSD17B10 Q99714 1/20 0.48
P2RY12 Q9H244 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5332048 0.84 TERT (1.00) TERTTNKSPARP1PARP15PARP14
SCHEMBL25811364 0.78 TERT (0.73) TERTKMT2A
SCHEMBL25811472 0.77 TERT (0.76) TERTMAPTALDH1A1TP53
SCHEMBL7143299 0.77 HTR1F (0.62) TERTHTR1FTNKSPARP1PARP15
SCHEMBL7139743 0.77 HTR1F (0.68) TERTHTR1FMAPTTNKSPARP1
SCHEMBL5337682 0.76 TERT (1.00) TERTP2RY12
SCHEMBL7138123 0.73 HTR1F (0.71) TERTHTR1FKMT2AKDM4EALDH1A1
SCHEMBL6937002 0.73 P2RX7 (0.57) KMT2A
SCHEMBL14174770 0.73 POLB (0.64) TERTKMT2ATP53
SCHEMBL5407770 0.72 ROCK2 (0.66) TERTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed
EP-4110463-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Galyan Bio, Inc. (US) 2023-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 TERT 4378/4885HTR1F 68/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.